Compass Therapeutics (NASDAQ:CMPX) Announces Earnings Results

Compass Therapeutics (NASDAQ:CMPX) issued its earnings results on Monday. The company reported ($0.15) EPS for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.03), FiscalAI reports.

Compass Therapeutics Price Performance

CMPX stock opened at $0.76 on Monday. The company has a market capitalization of $136.65 million, a P/E ratio of -1.90 and a beta of 1.06. The company has a 50-day simple moving average of $1.29 and a 200 day simple moving average of $3.10. Compass Therapeutics has a fifty-two week low of $0.67 and a fifty-two week high of $6.88.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on CMPX shares. Citizens Jmp dropped their price target on Compass Therapeutics to $4.00 and set a “market outperform” rating on the stock in a research report on Wednesday, September 23rd. Guggenheim reduced their price objective on Compass Therapeutics to $4.00 and set a “buy” rating for the company in a research report on Wednesday, September 23rd. Citigroup restated a “market outperform” rating on shares of Compass Therapeutics in a research report on Wednesday, September 23rd. Cantor Fitzgerald restated an “overweight” rating on shares of Compass Therapeutics in a research note on Wednesday, September 23rd. Finally, Piper Sandler increased their target price on Compass Therapeutics from $4.00 to $6.00 and gave the stock an “overweight” rating in a research report on Friday, August 7th. One investment analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $10.25.

About Compass Therapeutics

Compass Therapeutics is a clinical-stage biotechnology company focused on developing antibody-based medicines for cancer. The company’s research is centered on therapies designed to activate and direct the immune system against tumor cells, with the goal of improving immune responses in patients with cancer.

Its lead product candidate, CTX-471, is a fully human monoclonal antibody designed to activate CD137, also known as 4-1BB. CD137 is a co-stimulatory receptor found on immune cells, including T cells and natural killer cells.